Effect of Dietary Modifacation on Microbiota in Overweight and Obese Polycystic Ovary Syndrome Patients
Effect of Dietary Modifacation on Microbiota in Overweight and Obese Polycystic Ovary Syndrome Patients
Polycystic ovary syndrome (PCOS) is the most common endocrinopathy affecting women of
 reproductive age. The pathogenesis of PCOS is not fully understood. The intestinal microbiota
 are believed to be associated with the development of insulin resistance and obesity, and
 therefore contributing to the development of PCOS. Incresed permeability of the intestinal
 mucosal barier and absorbtion of lipoproteinase (LPS) from G (-) bacteria promotes chronic
 inflammation and may lead to insulin resistance.

 Approximately 50-60% of women suffering from PCOS are obese. It is known that lifestyle
 modification and body mass reduction improves endocrine parameters and restores ovulatory
 menstrual cycles in most patients. Currently, the use of probiotics and prebiotics is playing
 an increasingly important role in the treatment of obesity through the modulation of
 intestinal microflora.

 The objectives of the study are based on the following assumptions:

 1. Insulin resistance and compensatory hyperinsulinemia are important aspects in the
 pathogenesis of PCOS and co-morbidity of cardiovascular disease.

 2. Aberrations in the intestinal microflora are associated with the development of obesity
 and insulin resistance.

 3. Dietary modification combined with probiotic supplementation improves endocrine and
 metabolic profiles in women with PCOS.
Polycystic ovary syndrome (PCOS) is the most common endocrinopathy affecting women of
 reproductive age. The pathogenesis of PCOS is not fully understood. The intestinal microbiota
 are believed to be associated with the development of insulin resistance and obesity, and
 therefore contributing to the development of PCOS. Incresed permeability of the intestinal
 mucosal barier and absorbtion of lipoproteinase (LPS) from G (-) bacteria promotes chronic
 inflammation and may lead to insulin resistance.

 The microbiome consists of a complex community of microorganisms that live in the digestive
 tract. Intestinal microflora is colonized by various microorganisms, with the largest groups
 consisting of the Firmicutes, Bacteroides, Actinobacteria and Proteobacteria. Intestinal
 microflora has a beneficial effect on the host by competing with pathogenic bacteria,
 protecting the inegrity of the intestinal mucosal barier and stimulating the immune system.
 Some human gut microorganisms are involved In fermenting dietary fiber into short-chain fatty
 acids (SCFAs), such as acetic acid and butyric acid, which are then absorbed by the host. The
 most beneficial species of microbiota are Lactobacillus and Bifidobacterium.

 Approximately 50-60% of women suffering from PCOS are obese. It is known that lifestyle
 modification and body mass reduction improves endocrine parameters and restores ovulatory
 menstrual cycles in most patients. Currently, the use of probiotics and prebiotics is playing
 an increasingly important role in the treatment of obesity through the modulation of
 intestinal microflora.

 The objectives of the study are based on the following assumptions:

 1. Insulin resistance and compensatory hyperinsulinemia are important aspects in the
 pathogenesis of PCOS and co-morbidity of cardiovascular disease.

 2. Aberrations in the intestinal microflora are associated with the development of obesity
 and insulin resistance.

 3. Dietary modification combined with probiotic supplementation improves endocrine and
 metabolic profiles in women with PCOS.
Inclusion Criteria:

 1. Written consent for participation in the clinical trial

 2. Age 18 to 45 years Irregular menstruation (> 35 days) or secondary amenorrhea> 3
 months

 4. Hyperandrogenism (hirsutism and / or acne) and / or hyperandrogenemia (total serum
 testosterone> 0.5 ng / mL) 5. BMI > 25

 Exclusion Criteria:

 1. Ovarian cancer, adrenal gland tumor, endometrial cancer, cervical cancer, breast
 cancer

 2. Congenital adrenal hyperplasia (17-OH-progesterone> 2.5 ng / mL)

 3. Clinically diagnosed Cushing's disease, acromegaly, gigantism

 4. Type I or II diabetes

 5. Unexplained bleeding from the genital tract

 6. Hormone treatment within the last 2 months